What is the dosage of Aliqopa?

Aliqopa is available in 1 dosages, including 60 mg Injection

What does Aliqopa treat?

Aliqopa treats Follicular Lymphoma

What is Aliqopa made of?

Aliqopa contains copanlisib which is a Kinase Inhibitor

How is Aliqopa administered?

Aliqopa is administered as a Injectable

What is Aliqopa mechanism of action?

Aliqopa mechanism of action is Kinase Inhibitors

Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Patient education

Aliqopa

(copanlisib)

copanlisib 60 MG Injection [Aliqopa]

NO BLACK BOX WARNING

Dosage & administration

* Recommended dosage: 60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Modify dosage for toxicity .
* Reduce ALIQOPA dose to 45 mg in patients with moderate hepatic impairment (Child-Pugh B) or to 30 mg in patients with severe hepatic impairment (Child-Pugh C) .
* See full prescribing information for important preparation and administration information .

Aliqopa clinical details

Mechanism of Action (MOA)

Dosing & Administration Guide

Clinical Trials

Efficacy

Safety Profile

drug label

Aliqopa prescribing information

Have more Aliqopa questions?

Submit MSL Request

Learn More

Need to report an Aliqopa issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Aliqopa Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

Aliqopa Service Request Form

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Aliqopa Financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Enroll in Bridge Program

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Aliqopa Service Request Form

Bayer US Patient Assistance Program Application

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Aliqopa Patient education

Getting started on Aliqopa

NOT PROVIDED BY BRANDInstructions For Use - Follicular Lymphoma (FL)

Patient toolkit

About Aliqopa

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Brochure

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Learn More

Aliqopa FAQs

FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:

Please note:

Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.

Aliqopa

Dosage & administration

Most viewed Aliqopa resources

eficacy, safety & testing

Aliqopa clinical details

drug label

Aliqopa prescribing information

Have more Aliqopa questions?

Need to report an Aliqopa issue?

prior authorization

Aliqopa Prior authorization resources

Benefits investigation

Reimbursement help (FRM)

financial assistance

Aliqopa Financial assistance options

Co-pay savings program

Overview

Patient benefit

Patient eligibility

How to sign up

Bridge program

Overview

Patient benefit

Patient eligibility

How to sign up

Foundation programs

Overview

Patient benefit

Patient eligibility

How to sign up

patient education

Aliqopa Patient education

Getting started on Aliqopa

Patient toolkit

people also ask

Aliqopa FAQs

Can't find what you're looking for?